The story of the erectile dysfunction drug presents a challenging picture for investors. While the initial release generated massive gains, the end of its patent opened the avenue to generic versions, dramatically eroding sales. This creates a unique risk for pharmaceutical companies depending on

Are you dreaming that life-changing copyright win? Stop waiting and start boosting your bets with our legendary Explosions - guaranteed to saturate you with gains so massive, they'll leave your competitors shaking. Our insider knowledge